Our data suggest that the LRRK2 G2019S mutation enhances the production of IL-1β, IL-6 and IL-11 in the colon tumor microenvironment, thereby activating the NF-κB and STAT3 signaling pathways. This evidence concerns the gene IL1B and colonic neoplasm.